Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1436)	7/13/2002 5:06:13 PM
From: Biomaven	Respond to of 1477

Interesting. A couple of years back (late 2000) at a neuro conference presentation they (SKB at the time) said they had no plans to take this compound into the clinic. A quick google search now reveals this from a respiratory conference in May 2001: Dr DW Hay (GlaxoSmithKline, USA) outlined work with the p38 kinase inhibitor, SB 239063, in models that represent different pathological aspects of COPD. This compound reduced neutrophil infiltration, reduced inflammatory cytokine production (such as interleukin-6) and reduced matrix metalloproteinase-9 activity thus supporting the therapeutic potential of SB 239063 in the treatment of COPD. Dr Hay stated that the compound should be in the clinic within two to three years. Peter

To: scaram(o)uche who wrote (1436)	7/17/2002 6:45:49 PM
From: quidditch	Read Replies (1) \| Respond to of 1477

Rick, if I recall accurately SCIO's Q1 CC, management said that it was going to get a peek at toxicity indications in the current trial of SCIO 469 in the latter half of July. I believe that the same person on the call also said that there were not going to be any mid-trial efficacy indications. It seems likely that SCIO will disclose this anecdotal information at next week's meeting. (I may have it backward as to whether efficacy indications were to be revealed, but I don't think so.) quid